STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Rezolute Form 4 shows new equity awards to CEO Nevan Elam

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Rezolute, Inc. reported new equity awards to its CEO and director, Nevan C. Elam. On 11/19/2025, he received 317,000 common shares as restricted stock units at a price of $0, increasing his beneficial ownership to 609,119 common shares held directly.

He also received an employee stock option to buy 186,000 common shares at an exercise price of $10.16 per share. These options are exercisable through 11/19/2035. The restricted stock units vest annually over three years starting on December 1, 2026, and the options vest in equal monthly installments of 1/36 beginning on December 19, 2025.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Elam Nevan C

(Last) (First) (Middle)
C/O REZOLUTE, INC.
275 SHORELINE DRIVE, SUITE 500

(Street)
REDWOOD CITY CA 94065

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Rezolute, Inc. [ RZLT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
CEO
3. Date of Earliest Transaction (Month/Day/Year)
11/19/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares 11/19/2025 A 317,000(1) A $0 609,119 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Buy) $10.16 11/19/2025 A 186,000 (2) 11/19/2035 Common Shares 186,000 $0 186,000 D
Explanation of Responses:
1. Represents grant of restricted stock units which vest annually over a three-year period with the first RSUs vesting on December 1, 2026.
2. The options vest 1/36th monthly beginning on December 19, 2025.
/s/ Nevan C. Elam 11/21/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Rezolute (RZLT) report for Nevan C. Elam?

Rezolute reported that Nevan C. Elam, its CEO and director, received equity awards on 11/19/2025, including restricted stock units and stock options in Rezolute common shares.

How many Rezolute (RZLT) common shares were granted as restricted stock units?

The filing shows a grant of 317,000 common shares in the form of restricted stock units, recorded at a price of $0 per share.

What stock options were granted to the Rezolute (RZLT) CEO?

The CEO received an employee stock option for 186,000 common shares with an exercise price of $10.16 per share, expiring on 11/19/2035.

How and when do the Rezolute (RZLT) restricted stock units vest?

The 317,000 restricted stock units vest annually over a three-year period, with the first portion vesting on December 1, 2026.

What is the vesting schedule for the Rezolute (RZLT) stock options?

The 186,000 options vest in 1/36th monthly installments, beginning on December 19, 2025, until fully vested.

How many Rezolute (RZLT) common shares does Nevan C. Elam own after these transactions?

After the reported transaction, Nevan C. Elam beneficially owns 609,119 Rezolute common shares, held with direct ownership.

Rezolute Inc

NASDAQ:RZLT

RZLT Rankings

RZLT Latest News

RZLT Latest SEC Filings

RZLT Stock Data

886.48M
82.97M
9.68%
90.03%
8.53%
Biotechnology
Pharmaceutical Preparations
Link
United States
REDWOOD CITY